Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 2Myeloid 2Classical hematology 2Plasma cell 1Other solid neoplasm 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 228Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Molecular Diagnostic Techniques × Gastrointestinal × Clear all
NCT04600466 2026-04-14

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

The University of Texas Health Science Center at San Antonio

Terminated
129 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡